Market closed
Milestone Pharmaceuticals/$MIST
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
Ticker
$MIST
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Montreal, Canada
Employees
47
Website
MIST Metrics
BasicAdvanced
$123M
Market cap
-
P/E ratio
-$0.76
EPS
-
Beta
-
Dividend rate
Price and volume
Market cap
$123M
52-week high
$3.52
52-week low
$1.12
Average daily volume
413K
Financial strength
Current ratio
15.403
Quick ratio
14.923
Long term debt to equity
222.539
Total debt to equity
224.963
Interest coverage (TTM)
-12.38%
Management effectiveness
Return on assets (TTM)
-32.06%
Return on equity (TTM)
-162.87%
Valuation
Price to book
5.13
Price to tangible book (TTM)
5.13
Growth
Revenue change (TTM)
-100.00%
Earnings per share change (TTM)
-44.86%
3-year earnings per share growth (CAGR)
-3.48%
What the Analysts think about MIST
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Milestone Pharmaceuticals stock.
MIST Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
MIST Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
MIST News
AllArticlesVideos
Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update
GlobeNewsWire·1 week ago
Milestone Partner Ji Xing Pharmaceuticals Ltd Announces Positive Topline Results from the Phase 3 Study of Etripamil in PSVT in China
GlobeNewsWire·3 months ago
Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Milestone Pharmaceuticals stock?
Milestone Pharmaceuticals (MIST) has a market cap of $123M as of November 22, 2024.
What is the P/E ratio for Milestone Pharmaceuticals stock?
The price to earnings (P/E) ratio for Milestone Pharmaceuticals (MIST) stock is 0 as of November 22, 2024.
Does Milestone Pharmaceuticals stock pay dividends?
No, Milestone Pharmaceuticals (MIST) stock does not pay dividends to its shareholders as of November 22, 2024.
When is the next Milestone Pharmaceuticals dividend payment date?
Milestone Pharmaceuticals (MIST) stock does not pay dividends to its shareholders.
What is the beta indicator for Milestone Pharmaceuticals?
Milestone Pharmaceuticals (MIST) does not currently have a Beta indicator.